Literature DB >> 12445836

Altered glucocorticoid immunoregulation in treatment resistant depression.

Moisés E Bauer1, Andrew Papadopoulos, Lucia Poon, Paula Perks, Stafford L Lightman, Stuart Checkley, Nola Shanks.   

Abstract

Alterations in cellular immune function are associated with depression and have been related to changes in endocrine function. We carried out a study to: (i) reliably assess the hypothalamic-pituitary-adrenal (HPA) axis function in treatment resistant depression (TRP); (ii) evaluate whether depression was associated with changes on T-cell proliferation and cytokine production; and (iii) assessed the sensitivity of lymphocytes to glucocorticoids (GC)s in vitro. Thirty-six pharmacologically treated inpatients diagnosed with TRP and 31 healthy controls took part in the study. Salivary cortisol was measured hourly from 0800 to 2200 h both before and after dexamethasone (DEX) intake and the patients were classified into HPA axis suppressors and nonsuppressors. The following were measured in vitro: (a) phytohemagglutinin-induced T-cell proliferation; (b) cytokine production (interleukin-2 and tumor necrosis factor-alpha, TNF-alpha); and (c) lymphocyte sensitivity to both cortisol and DEX. Basal morning cortisol levels from patients and controls did not differ nor did their T-cell proliferation and cytokine production. Ten out of 36 patients were classified as nonsuppressors and presented a significantly higher post-DEX salivary cortisol levels than suppressors, 82.0 vs 8.9 nM/l/h (p <0.001). Cells of nonsuppressors produced significantly less TNF-alpha compared to suppressors, 299.8 vs 516.9 pg/ml (p < 0.05). Remarkably, GC-induced suppression of lymphocyte proliferation and cytokine production were generally less marked in depressives compared with controls. Our data indicate that alterations in immune function and steroid regulation associated with depression are not related to elevated basal levels of cortisol and suggest that lymphocyte steroid resistance may be associated with TRP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12445836     DOI: 10.1016/s0306-4530(02)00009-4

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  17 in total

Review 1.  Immune system to brain signaling: neuropsychopharmacological implications.

Authors:  Lucile Capuron; Andrew H Miller
Journal:  Pharmacol Ther       Date:  2011-02-17       Impact factor: 12.310

Review 2.  Glucocorticoid regulation of clock gene expression in the mammalian limbic forebrain.

Authors:  Lauren A Segall; Shimon Amir
Journal:  J Mol Neurosci       Date:  2010-02-27       Impact factor: 3.444

Review 3.  Targeting the Adaptive Immune System in Depression: Focus on T Helper 17 Cells.

Authors:  Eléonore Beurel; Eva M Medina-Rodriguez; Richard S Jope
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

Review 4.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

5.  Interleukin-1 receptor type 1-deficient mice fail to develop social stress-associated glucocorticoid resistance in the spleen.

Authors:  Harald Engler; Michael T Bailey; Andrea Engler; LaTonia M Stiner-Jones; Ning Quan; John F Sheridan
Journal:  Psychoneuroendocrinology       Date:  2007-11-26       Impact factor: 4.905

Review 6.  Depression and immunity: a role for T cells?

Authors:  Andrew H Miller
Journal:  Brain Behav Immun       Date:  2009-10-08       Impact factor: 7.217

7.  Different responses to dexamethasone and prednisolone in the same depressed patients.

Authors:  Mario F Juruena; Anthony J Cleare; Andrew S Papadopoulos; Lucia Poon; Stafford Lightman; Carmine M Pariante
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

8.  Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'.

Authors:  Annamaria Cattaneo; Massimo Gennarelli; Rudolf Uher; Gerome Breen; Anne Farmer; Katherine J Aitchison; Ian W Craig; Christoph Anacker; Patricia A Zunsztain; Peter McGuffin; Carmine M Pariante
Journal:  Neuropsychopharmacology       Date:  2012-09-19       Impact factor: 7.853

9.  Modulation of cortisol responses to the DEX/CRH test by polymorphisms of the interleukin-1beta gene in healthy adults.

Authors:  Daimei Sasayama; Hiroaki Hori; Yoshimi Iijima; Toshiya Teraishi; Kotaro Hattori; Miho Ota; Takashi Fujii; Teruhiko Higuchi; Naoji Amano; Hiroshi Kunugi
Journal:  Behav Brain Funct       Date:  2011-07-05       Impact factor: 3.759

10.  Quest for biomarkers of treatment-resistant depression: shifting the paradigm toward risk.

Authors:  Donald F Smith
Journal:  Front Psychiatry       Date:  2013-06-18       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.